VivoSeq
Other

CLL

8

Pipeline Programs↗

10

Active Trials↗

9

Companies Involved↗

CLL is an early-stage landscape with 8 programs across 9 companies. The most active players are BeOne Medicines, Roche, Gilead. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

40/100

Completion Rate

41/100

Attrition Rate

36/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

BeOne Medicines

3 programs

Phase 3Roche logo

Roche

2 programs

Phase 3Gilead logo

Gilead

1 program

Phase 3A

Azurity Pharmaceuticals

1 program

Phase 3AbbVie logo

AbbVie

1 program

Phase 3A

Acerta Pharma BV

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 38

BGB-16673

BeOne Medicines

Bendamustine

Azurity Pharmaceuticals

Idelalisib

Gilead

Rituximab

Roche

Venetoclax

AbbVie

Approved
No programs

Analysis

Modality Breakdown

75%

Small molecule

6 of 8 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody225%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

28

clinical trials

Terminated7 · 25%
Completed7 · 25%
Recruiting6 · 21%
Active, not recruiting3 · 11%
Withdrawn3 · 11%
Not yet recruiting1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

28 trials

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03128879·90 enrolled
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Recruiting·—·Phase 2·NCT05168930·45 enrolled
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Recruiting·MMassachusetts General Hospital·Phase 2·NCT04560322·40 enrolled
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT05950997·89 enrolled
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors
Recruiting·BBeOne Medicines·Phase 3·NCT06846671·250 enrolled
Study of the Metabolic Reprogramming of CLL Cells in Ex-vivo Models of the Lymphatic Niche
Recruiting·CCentre Hospitalier Universitaire de Nice·N/A·NCT05610228·30 enrolled
Safe Accelerated Venetoclax Escalation in CLL
Active, not recruiting·—·Phase 1·NCT04843904·40 enrolled
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Active, not recruiting·AAcerta Pharma BV·Phase 3·NCT02970318·310 enrolled
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Active, not recruiting·BBeOne Medicines·Phase 3·NCT06073821·652 enrolled
Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens
Not yet recruiting·—·Phase 4·NCT04790045·30 enrolled
Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
Completed·FFrench Innovative Leukemia Organisation·Phase 3·NCT00564512·178 enrolled
A Phase I/II Study of GX15-070MS in Untreated CLL
Completed·—·Phase 1·NCT00600964·26 enrolled
Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients
Completed·GSK logoGSK·Phase 2·NCT00410163·61 enrolled
GIMEMA CLL0809 Study (BendOfa)
Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT01244451·49 enrolled
Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients
Completed·AAdvancell - Advanced In Vitro Cell Technologies, S.A.·Phase 1/2·NCT00559624·40 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)